Pulse Biosciences Stock News

ROSEN, A TOP RANKED FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Actio

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the “Class Period”), of the important April 18, 2022 lead plaintiff deadline .

NEW YORK--(BUSINESS WIRE)-- #Biosciences--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the “Class Period”), of the important April 18, 2022 lead plaintiff deadline. SO WHAT: If you purchased Pulse securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO

SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January 12, 2021 and February 7, 2022, both dates inclusive (the “Class Period”) have until April 18, 2022 to seek appointment as lead plaintiff in Ngosiok v. Pulse Biosciences, Inc ., No. 22-cv-00959 (N.D. Cal.). Commenced on February 16, 2022 and assigned to Judge Charles R. Breyer, the Pulse Biosciences class action lawsuit charges Pulse Biosciences as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022 .

SAN DIEGO--(BUSINESS WIRE)---- $PLSE #attorney--Pulse Biosciences, Inc. (PLSE) Misstated the Viability of its CellFX System for Treating Sebaceous Hyperplasia Lesions

SAN DIEGO, Feb. 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January 12, 2021 and February 7, 2022, both dates inclusive (the Class Period) have until April 18, 2022 to seek appointment as lead plaintiff in Ngosiok v. Pulse Biosciences, Inc ., No. 22-cv-00959 (N.D. Cal.). Commenced on February 16, 2022, the Pulse Biosciences class action lawsuit charges Pulse Biosciences as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO, Feb. 19, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January 12, 2021 and February 7, 2022, inclusive (the "Class Period") have until April 18, 2022 to seek

LOS ANGELES--(BUSINESS WIRE)---- $PLSE #PLSE--The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $PLSE #attorney--Pulse Biosciences, Inc. (PLSE) Misstated the Viability of its CellFX System for Treating Sebaceous Hyperplasia Lesions

NEW YORK--(BUSINESS WIRE)---- $PLSE #PLSE--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022. SO WHAT: If you purchased Pulse securities during the Class P

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Pulse securities between January 12, 2021 and February 7, 2022, both dates inclusive (the “Class Period”). In

SAN DIEGO--(BUSINESS WIRE)-- #PLSEstock--The suit alleges defendants issued false statements re: Pulse Biosciences business & prospects, resulting in its stock trading at inflated prices.